CB-86 is a synthetic cannabinoid drug which was developed as a hybrid between classical/nonclassical cannabinoids such as THC and CP 47,497 with endogenous cannabinoid ligands such as anandamide. It acts as a partial agonist at CB1 receptors with a K<sub>i</sub> of 5.6 nM, and an antagonist of CB2 receptors with a K<sub>i</sub> of 7.9 nM. It has analgesic effects in studies on mice.